MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design-Reference-Cited by-同舟云学术

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

Published:2018-08-03 Issue:1 Volume:19 Page:
ISSN:1471-2164
Container-title:BMC Genomics
language:en
Short-container-title:BMC Genomics

Author:

Cai Weijing,Zhou Dapeng^ORCID,Wu Weibo,Tan Wen Ling,Wang Jiaqian,Zhou Caicun,Lou Yanyan

Funder

National Natural Science Foundation of China grant

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Biotechnology

Link

http://link.springer.com/content/pdf/10.1186/s12864-018-4958-5.pdf

Reference27 articles.

1. Sun Z, Chen F, Meng F, Wei J, Liu B. MHC class II restricted neoantigen: a promising target in tumor immunotherapy. Cancer Lett. 2017;392:17–25.

2. Flament H, Alonso Ramirez R, Prémel V, Joncker NT, Jacquet A, Scholl S, Lantz O. Modeling the specific CD4+ T cell response against a tumor neoantigen. J Immunol. 2015;194(7):3501–12. https://doi.org/10.4049/jimmunol.1402405 . Epub 2015 Mar 2. Erratum in: J Immunol. 2017 Aug 15;199(4):1526

3. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol. 1992;10:617–44.

4. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stevanović S, Riemer AB, Sahin U, Friese MA, Beckhove P, von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–7.

5. Nielsen JS, Chang AR, Wick DA, Sedgwick CG, Zong Z, Mungall AJ, Martin SD, Kinloch NN, Ott-Langer S, Brumme ZL, Treon SP, Connors JM, Gascoyne RD, Webb JR, Berry BR, Morin RD, Macpherson N, Nelson BH. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017;6(7):e1321184.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subclassification of lung adenocarcinoma through comprehensive multi-omics data to benefit survival outcomes;Computational Biology and Chemistry;2024-10

2. HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy;Cancers;2024-09-07

3. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma;International Immunopharmacology;2024-09

4. Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer;Translational Lung Cancer Research;2024-06

5. Bioinformatics Analysis Identifies PLA2G7 as a Key Antigen-Presenting Prognostic Related Gene Promoting Hepatocellular Carcinoma through the STAT1/PD-L1 Axis;Frontiers in Bioscience-Landmark;2024-01-23